Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study. Journal Abstract

Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study.

Publication Date: 2024 Jun

Full Text Sources

Authors

Peter Ueda; Viktor Wintzell; Mads Melbye; Björn Eliasson; Jonas Söderling; Soffia Gudbjörnsdottir; Kristian Hveem; Christian Jonasson; Henrik Svanström; Anders Hviid; Björn Pasternak

Abstract

OBJECTIVE

Concerns have been raised that the incretin-based diabetes drugs dipeptidyl peptidase 4 (DPP4) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists may increase the risk of intestinal obstruction. We aimed to assess the association between use of DPP4 inhibitors and GLP-1 receptor agonists and the risk of intestinal obstruction.

Source

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Pub Types(s)

Journal Article

Language

English

PubMed ID

37716613